AmplifiDx (www.amplifidx.com), an “up-and-coming” player in point-of-care (POC) molecular diagnostics, is pleased to announce that it has been awarded an additional $954,213 in non-dilutive funding from the NIH’s Rapid Acceleration of Diagnostics (RADx®) Tech program. This award brings the company’s total NIH funding to $4.51 million through the RADx® Tech program.

AmplifiDx Inc., an emerging player in Molecular Diagnostics, is proud to announce that it has been awarded $1.38 million in funding from the National Institutes of Health (NIH) through the Rapid Acceleration of Diagnostics (RADx®) Tech program. This award provides an opportunity for AmplifiDx to secure more funding if milestones are met.